News and Info

Welcome to the News and Information section of the ECOG-ACRIN Cancer Research Group website. The materials posted in this section are intended to keep constituents informed of the latest news and activities of the organization. The information below includes press releases, announcements, media advisories, and links to news articles.

We welcome inquiries from members of the press regarding the information posted on this website. To place a media inquiry, contact the Office of Communications.


Latest News

October 13, 2022

The September/October 2022 News from ECOG-ACRIN blog is now available

October 4, 2022

DREAMseq trial clarifies immunotherapy, targeted treatment order for patients with BRAF-mutant metastatic melanoma

September 30, 2022

Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy

September 28, 2022

Immunotherapy before targeted therapy improves survival in advanced melanoma, according to the DREAMseq trial

September 27, 2022

Media Advisory: Journal of Clinical Oncology publishes outcomes from the practice-changing DREAMseq trial in patients with advanced melanoma

September 26, 2022

The Fall 2022 advocacy blog Considering Clinical Trials is now available

September 8, 2022

Press Release: ECOG-ACRIN completes the first randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

August 16, 2022

The August 2022 News from ECOG-ACRIN blog is now available

August 10, 2022

President Biden announces his intent to appoint Dr. Monica Bertagnolli as the next NCI director

August 9, 2022

Early-career investigators: Submit an abstract for the 2022 Young Investigator Symposium by Wednesday, 9/7

July 21, 2022

Group co-chairs Peter O’Dwyer and Mitch Schnall commend the selection of Monica Bertagnolli as the next NCI director

July 15, 2022

Ongoing Smoke Free Support Study 2.0 featured in BioMed Central’s Public Health Journal

July 14, 2022

Media Advisory: Blood publishes long-term outcomes of patients with CLL in the practice-changing E1912 trial

July 2, 2022

What is ECOG-ACRIN EA2142? And why should you care?

June 28, 2022

The Summer 2022 advocacy blog, Considering Clinical Trials, is now available

June 22, 2022

FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH

June 20, 2022

TMIST breast cancer trial looks to recruit underserved communities

June 7, 2022

Pancreatic neuroendocrine tumors: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

June 7, 2022

E2108 evidence informs a discussion on systemic therapy vs surgery for de novo stage IV breast cancer

June 6, 2022

Novel drug combination demonstrates promising results in treating pancreatic neuroendocrine tumors

 
ECOG-ACRIN Cancer Research Group